Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493
Epigenetic Regulation01:37

Epigenetic Regulation

3.0K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
3.0K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

861
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
861
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. H3k9 Lactylation In Malignant Cells Facilitates Cd8+ T Cell Dysfunction And Poor Immunotherapy Response

H3K9 lactylation in malignant cells facilitates CD8+ T cell dysfunction and poor immunotherapy response

Ruijie Wang1, Chuwen Li1, Zhongyi Cheng2

  • 1Department of Oral Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China; National Center for Stomatology & National Clinical Research Center for Oral Diseases, Shanghai 200011, China; Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, Shanghai 200011, China.

Cell Reports
|August 31, 2024

Related Experiment Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.4K
Isolation and Cultivation of Neural Progenitors Followed by Chromatin-Immunoprecipitation of Histone 3 Lysine 79 Dimethylation Mark
10:09

Isolation and Cultivation of Neural Progenitors Followed by Chromatin-Immunoprecipitation of Histone 3 Lysine 79 Dimethylation Mark

Published on: January 26, 2018

7.4K
Measuring Mitochondrial Function of Naïve and Effector CD8 T Cells
06:07

Measuring Mitochondrial Function of Naïve and Effector CD8 T Cells

Published on: March 28, 2025

213

View abstract on PubMed

Summary
This summary is machine-generated.

Histone lactylation (Kla) in head and neck cancer predicts poor immunotherapy response. Targeting interleukin-11 (IL-11) can reverse immune suppression and improve treatment outcomes.

Area of Science:

  • Oncology
  • Immunology
  • Epigenetics

Background:

  • Histone lysine lactylation (Kla) is an emerging post-translational modification.
  • The role of Kla in tumor immune escape is not well understood.
  • Head and neck squamous cell carcinoma (HNSCC) often shows resistance to immunotherapy.

Purpose of the Study:

  • To investigate the role of histone lactylation in HNSCC immune escape.
  • To identify specific lactylation sites and their downstream targets.
  • To explore potential therapeutic strategies targeting lactylation for improved immunotherapy.

Main Methods:

  • Analysis of histone lactylation in HNSCC patient samples.
  • Identification of specific lactylation sites (H3K9la) and downstream genes (IL-11) using CUT&Tag.
Keywords:
CP: CancerCP: MetabolismT cell dysfunctionhead and neck squamous cell carcinoma

Related Experiment Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.4K
Isolation and Cultivation of Neural Progenitors Followed by Chromatin-Immunoprecipitation of Histone 3 Lysine 79 Dimethylation Mark
10:09

Isolation and Cultivation of Neural Progenitors Followed by Chromatin-Immunoprecipitation of Histone 3 Lysine 79 Dimethylation Mark

Published on: January 26, 2018

7.4K
Measuring Mitochondrial Function of Naïve and Effector CD8 T Cells
06:07

Measuring Mitochondrial Function of Naïve and Effector CD8 T Cells

Published on: March 28, 2025

213
  • Investigation of IL-11 signaling pathways (JAK2/STAT3) in CD8+ T cells.
  • In vivo studies using IL11 knockdown and cholesterol-modified siIL11.

    • Main Results:

    • Increased histone lactylation, specifically H3K9la, correlates with poor immunotherapy response in HNSCC.
    • H3K9la directly regulates Interleukin-11 (IL-11) transcription.
    • IL-11 activates immune checkpoint genes in CD8+ T cells via JAK2/STAT3 signaling, promoting tumor progression and T cell dysfunction.
    • IL11 knockdown and cholesterol-modified siIL11 reversed immune suppression and enhanced immunotherapy efficacy in vivo.

    Conclusions:

    • Histone lactylation, particularly H3K9la, is a key driver of immune escape in HNSCC.
    • The H3K9la-IL-11-JAK2/STAT3 axis represents a novel mechanism of immune suppression.
    • Targeting IL-11 offers a promising strategy to overcome immunotherapy resistance in HNSCC.
    histone lactylation
    interleukin-11
    tumor microenvironment